- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01803451
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass (GLP-1)
The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
- To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp.
- To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
- To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
- To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp.
- To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
- To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Marzieh Salehi, MD MS
- Phone Number: 210-567-6691
- Email: salehi@uthscsa.edu
Study Contact Backup
- Name: Andrea Hansis-Diarte
- Phone Number: 210-567-6691
- Email: hansisdiarte@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78207
- Recruiting
- Texas Diabetes Institute - University Health System
-
Contact:
- Andrea Hansis-Diarte, MPh
- Phone Number: 210-567-6691
- Email: hansisdiarte@uthscsa.edu
-
Contact:
- Marzieh Salehi, MD, MS
- Phone Number: 210-567-6691
- Email: salehi@uthscsa.edu
-
San Antonio, Texas, United States, 78229
- Recruiting
- South Texas Veterans Health Care System
-
Contact:
- Marzieh Salehi, MD MS
- Phone Number: 210-567-6691
- Email: salehi@uthscsa.edu
-
Contact:
- Andrea Hansis-Diarte
- Phone Number: 210-567-6691
- Email: hansisdiarte@uthscsa.edu
-
Principal Investigator:
- Marzieh Salehi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18-65
- healthy control without diabetes or active organ disease
- Individuals with bariatric surgery
- recurrent hypoglycemia post gastric bypass
Exclusion Criteria:
- pregnancy
- significant anemia
- diabetes currently unless pre-op for bariatric surgery procedure
- GI obstruction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hyperglycemic clamp-Meal tolerance test
these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
|
hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
Other Names:
|
Experimental: Labeled meal tolerance test
The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
|
2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated
Time Frame: up to 1 year (10 sessions)
|
up to 1 year (10 sessions)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marzieh Salehi, MD,MS, Marzieh Salehi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HSC20180070H
- DK083554 (Other Grant/Funding Number: NIDDK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-bariatric Surgery
-
University of Texas Southwestern Medical CenterCompleted
-
Hospices Civils de LyonRecruitingPost-operative Complications After Colorectal Surgery | Post-operative Complications After Gastric Surgery | Post-operative Complications After Bariatric SurgeryFrance
-
TakedaWithdrawnWeight Regain Post Bariatric SurgeryUnited States
-
Unidad Internacional de Cirugia Bariatrica y MetabolicaRecruitingGERD | Bariatric Surgery Candidate | Revisional Bariatric SurgeryVenezuela
-
Multan Medical And Dental CollegeCompleted
-
Universidad de ZaragozaCentro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas... and other collaboratorsRecruitingBariatric Surgery | Bariatric Surgery and Whole Body Vibration TrainingSpain
-
Cairo UniversityBatterjee Medical College; Taif UniversityCompletedSurgery | Bariatric SurgeryEgypt, Saudi Arabia
-
University of Illinois at Urbana-ChampaignCarle Foundation HospitalRecruitingBariatric Surgery Candidate | Bariatric Surgical ProcedureUnited States
-
McMaster UniversityNot yet recruitingRobotic Surgery | Bariatric Surgery
-
Western Galilee Hospital-NahariyaCompletedBariatric Patients Undergoing Bariatric SurgeryIsrael
Clinical Trials on exendin-(9-39)
-
Tracey McLaughlinUnknownHyperinsulinemia HypoglycemiaUnited States
-
University Hospital, Gentofte, CopenhagenUniversity of CopenhagenCompletedGlucose Metabolism DisordersDenmark
-
University Hospital, Basel, SwitzerlandCompletedAppetite and General Nutritional DisordersSwitzerland
-
University Hospital, Gentofte, CopenhagenUniversity of CopenhagenCompletedGlucose Metabolism DisordersDenmark
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDyspepsia | Diabetes Mellitus With Gastrointestinal SymptomsUnited States
-
Tracey McLaughlinUnknown
-
Adrian VellaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedType 2 Diabetes MellitusUnited States
-
Blandine LaferrereNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedType 2 Diabetes MellitusUnited States
-
Tracey McLaughlinEiger BioPharmaceuticalsCompletedPost Bariatric HypoglycemiaUnited States